<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00980408</url>
  </required_header>
  <id_info>
    <org_study_id>RH999</org_study_id>
    <nct_id>NCT00980408</nct_id>
  </id_info>
  <brief_title>The Influence of Glutamate on Memory in Humans</brief_title>
  <official_title>The NMDA Receptor Co-agonist D-cycloserine Accelerates Associative Learning in the Human Hippocampal CA Region</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <brief_summary>
    <textblock>
      The hippocampus is particularly laden with n-methyl-d-aspartate (NMDA) receptors, and is at
      the same time one of the most important sites in declarative memory. The rationale of this
      study is that the NMDA partial agonist D-Cycloserine will promote learning compared to a
      placebo. On the other hand, the NMDA receptor antagonist Memantine might lead to reduced
      memory. We believe that the influence of NMDA receptors on memory can be determined via acute
      co-activation of the NMDA receptors with Cycloserine® (King Pharmaceuticals Ltd, active
      ingredient: DCycloserin, dose: 250 mg) and Memantine (Axura®, Merz, active ingredient:
      Memantine, dose: 20 mg)on both a behavioral and functional (fMRI) level.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fMRI during learning task</measure>
    <time_frame>once at drug administration</time_frame>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Healthy Individuals</condition>
  <arm_group>
    <arm_group_label>Sugar pill, behavioral glutamic acid</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo condition for D-Cycloserine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill, fMRI, glutamic acid</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo condition for D-Cycloserine, fMRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill, memantine, behavioral</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo condition Memantine, behavioral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill, memantine, fMRI</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo condition Memantine, fMRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D-Cycloserine behavioral</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>D-Cycloserine, fMRI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Memantine, behavioral</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Memantine, fMRI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugar pill</intervention_name>
    <description>250 mg, one dose, 60 min prior</description>
    <arm_group_label>Sugar pill, behavioral glutamic acid</arm_group_label>
    <other_name>Placebo condition for D-Cycloserine, behavioral study</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugar pill</intervention_name>
    <description>250 mg, one dose, 60 min prior</description>
    <arm_group_label>Sugar pill, fMRI, glutamic acid</arm_group_label>
    <other_name>Placebo condition for D-Cycloserine, fMRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugar pill</intervention_name>
    <description>20 mg, one dose, 8 hours prior</description>
    <arm_group_label>Sugar pill, memantine, behavioral</arm_group_label>
    <other_name>Placebo condition Memantine, behavioral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugar pill</intervention_name>
    <description>20 mg, one dose, 8 hours prior</description>
    <arm_group_label>Sugar pill, memantine, fMRI</arm_group_label>
    <other_name>Placebo condition Memantine, fMRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glutamic Acid</intervention_name>
    <description>250 mg, one dose, 60 minutes prior</description>
    <arm_group_label>D-Cycloserine behavioral</arm_group_label>
    <other_name>D-Cycloserine, King Pharmaceuticals</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glutamic Acid</intervention_name>
    <description>250 mg, one dose, 60 minutes prior</description>
    <arm_group_label>D-Cycloserine, fMRI</arm_group_label>
    <other_name>D-Cycloserine, King Pharmaceuticals</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine</intervention_name>
    <description>20 mg, one dose, 8 hours prior</description>
    <arm_group_label>Memantine, behavioral</arm_group_label>
    <other_name>Axura, Merz</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine</intervention_name>
    <description>20 mg, one dose, 8 hours prior</description>
    <arm_group_label>Memantine, fMRI</arm_group_label>
    <other_name>Axura, Merz</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  German native language or native language level

          -  Able to give written informed consent

          -  right-handed

        Exclusion Criteria:

          -  inability to give written informed consent, underaged minors, contractually incapable
             persons, persons in legal custody

          -  any psychiatric, neurological or internal illness

          -  hematoporphyria (enzyme sickness)

          -  intake of medication (except oral contraceptives)

          -  simultaneous participation in other clinical studies

          -  hypersensitivity to Memantine or other anti-dementia substances, or to D-Cycloserine

          -  alcohol abuse

          -  epilepsy

          -  depression

          -  serious anxiety or psychosis

          -  serious kidney insufficiency

          -  intake of Ethionamide or Isoniazide

          -  pregnancy or women who are nursing

          -  liver or kidney problems

          -  intake of NMDA-antagonists, such as Amantadine, Ketamine, or Dextromethorphan

          -  vegetarians

          -  stomach ulcer, if treated with medication

          -  renal tubular acidosis

          -  urinary infections (with proteus bacteria)

          -  recent heart attack, heart failure, or uncontrolled high blood pressure

          -  intake of L-Dopa, dopaminergic agonists, and anticholinergics

          -  intake of barbiturates, spasmolytics, Phenytoin, Amantadine, oral coagulators,
             warfarin, HCT (Hydrochlorothiazide)

          -  heart or cranial operations

          -  pacemaker, medication pump (such as insulin pump), hearing aid, removable
             prosthodontics

          -  metal in or on body (such as acupuncture needles, artificial limbs, stents, metal
             splints, clips, implanted electrodes, tattoos, or piercings)

          -  claustrophobia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Forschungszentrum Juelich GmbH</name>
      <address>
        <city>Juelich</city>
        <state>NRW</state>
        <zip>52428</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2009</study_first_submitted>
  <study_first_submitted_qc>September 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2009</study_first_posted>
  <last_update_submitted>December 2, 2014</last_update_submitted>
  <last_update_submitted_qc>December 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Bonn</investigator_affiliation>
    <investigator_full_name>Rene Hurlemann</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
    <mesh_term>Cycloserine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

